(NASDAQ: SLDB) Solid Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.
Solid Biosciences's earnings in 2025 is -$154,084,000.On average, 15 Wall Street analysts forecast SLDB's earnings for 2025 to be -$158,642,658, with the lowest SLDB earnings forecast at -$213,750,600, and the highest SLDB earnings forecast at -$143,247,943. On average, 14 Wall Street analysts forecast SLDB's earnings for 2026 to be -$154,461,089, with the lowest SLDB earnings forecast at -$204,819,017, and the highest SLDB earnings forecast at -$109,561,783.
In 2027, SLDB is forecast to generate -$138,046,289 in earnings, with the lowest earnings forecast at -$191,846,030 and the highest earnings forecast at -$114,467,534.